Industry News
Pharmaceutical Industry News
Galderma Laboratories has landed a…
Galderma Laboratories has landed a blow on Sanofi in its multi-case advertising row, driving the French drugmaker to change or drop certain claims about its blockbuster medicine Dupixent.
F.D.A. Approves Moderna’s mRNA Flu Vaccine
The agency had initially refused to even review the application but reversed course after a public outcry.
Despite a major curveball thrown…
Despite a major curveball thrown by the FDA earlier this year, Moderna has managed to strike true with a U.S. approval for its mRNA-based influenza vaccine.
Two and a half years into his…
Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to align the business with “current business realities.”
ViiV Healthcare is urging people…
ViiV Healthcare is urging people to think about how today’s HIV prevention and treatment choices could shape their future. Its new “Do It For Future You” campaign spotlights long-acting options through a digital push that
AstraZeneca and CSPC…
AstraZeneca and CSPC Pharmaceutical are strengthening their partnership by establishing a new biologics manufacturing joint venture in China.
Alcon’s back-to-school campaign…
Alcon's back-to-school campaign for its Precision contact lenses looks to help eye doctors better reach their Gen Z patients.
Gilead’s HIV prevention business…
Gilead’s HIV prevention business reached a milestone, exceeding $1 billion in quarterly sales for the first time, as highlighted by CEO Daniel O’Day. But one group of analysts is raising doubts about the long-term growth
Novo’s Wegovy pill thesis…
Novo’s Wegovy pill thesis continues to bear out in 2026, as the oral obesity med keeps impressive sales apace while sparing pre-existing prescriptions tied to the company’s injectable GLP-1.
Eli Lilly reported $98 million in…
Eli Lilly reported $98 million in second-quarter sales for Foundayo, its newly launched oral GLP-1 treatment, lagging far behind rival Novo Nordisk's Wegovy pill.
Fujifilm Biotechnologies passed…
Fujifilm Biotechnologies passed the leadership reins to Maja Pedersen, adding president to her current role as COO while former Chief Executive Lars Petersen transitions to a strategic advisor position.
AstraZeneca and Bristol Myers…
AstraZeneca and Bristol Myers Squibb do not have any ongoing discussions about a potential deal, Reuters reported Wednesday, citing a senior source close to the matter.
Weber Shandwick and Reddit…
Weber Shandwick and Reddit partnered up in a July report that aims to decode the “new health ecosystem” and the modern women’s health content discovery journey, which, as it turns out, takes place on Reddit.
The PCSK9 cholesterol drug class…
The PCSK9 cholesterol drug class has long been viewed as one of the biggest hype-to-disappointment stories in pharmaceutical history. Merck aims to flip that narrative with Lipfendra, betting the first-ever oral option can finally unlock
Years of litigation surrounding…
Years of litigation surrounding Gilead Sciences’ tenofivor-based HIV treatments have come to an end, with the California Supreme Court taking Gilead’s side in a ruling that sets a key precedent for innovative drugmakers.
As Amgen’s flagship PCSK9…
As Amgen’s flagship PCSK9 cholesterol drug Repatha enjoys a bit of a renaissance on the back of impressive cardiovascular risk reduction data last year, the company is confident it can keep that momentum running well
Johnson & Johnson has named…
Johnson & Johnson has named Tom Cavanaugh as the next leader of its innovative medicines business, beginning Sept. 1, 2026.
Pfizer will reduce its costs by…
Pfizer will reduce its costs by $2.5 billion in another round of cutbacks, which will begin next year and run through 2029. The additional cost savings swell Pfizer's program to $9.7 billion in reductions.
With Bayer’s pharma sales growth…
With Bayer’s pharma sales growth lagging behind its crop science and consumer health divisions in the second quarter, analysts once again raised the possibility of major changes to the German conglomerate’s group structure.
Book Review: ‘The Ego Trip,’ by Kimon de Greef
Kimon de Greef’s “The Ego Trip” is an enthralling, galling journey into the deeply weird underbelly of the psychedelic renaissance.